Ultragenyx Pharmaceutical Inc. (RARE) 54.10 $RARE
Ultragenyx Announces Positive 36-Week Data From Phase 1/2 Study of Recombinant Human Beta-Glucuronidase in Mucopolysaccharidosis 7
GlobeNewswire - Tue Feb 10, 3:30PM CST
Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced the presentation of positive 36-week data from the Phase 1/2 study of recombinant human beta-glucuronidase (rhGUS, UX003), an investigational therapy for the treatment of Mucopolysaccharidosis 7 (MPS 7, Sly syndrome). The data are being presented in poster and oral presentations by Dr. Emil Kakkis, Chief Executive Officer of Ultragenyx, at the 11Annual WORLD Symposium in Orlando, Florida.
RARE: 54.10 (+0.12)
Ultragenyx prices public offering at USD54.00 per share
M2 - Fri Feb 06, 4:21AM CST
Biopharmaceutical company Ultragenyx Pharmaceutical (NasdaqGS:RARE) said on Thursday that it has priced a public offering of 3,000,000 common stock shares.
RARE: 54.10 (+0.12)
Ultragenyx prices equity offering
Seeking Alpha - at Seeking Alpha - Thu Feb 05, 8:11AM CST
RARE: 54.10 (+0.12)
Ultragenyx Announces Pricing of Public Offering of Common Stock
GlobeNewswire - Wed Feb 04, 6:09PM CST
Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced the pricing of its underwritten public offering of 3,000,000 shares of its common stock at a price to the public of $54.00 per share, before underwriting discounts. In addition, the company has granted the underwriters of the offering an option for a period of 30 days to purchase up to an additional 450,000 shares of the company's common stock at the public offering price, less the underwriting discount.
RARE: 54.10 (+0.12)
Ultragenyx to issue up to USD125m of common stock in public offering
M2 - Wed Feb 04, 5:24AM CST
Biopharmaceutical company Ultragenyx Pharmaceutical (NasdaqGS:RARE) Tuesday reported the start of its planned public offering of up to USD125m of shares of its common stock.
RARE: 54.10 (+0.12)
Ultragenyx Announces Proposed Public Offering of Common Stock
GlobeNewswire - Tue Feb 03, 3:37PM CST
Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that it has commenced an underwritten public offering of up to $125,000,000 of shares of its common stock. In addition, the company is expected to grant the underwriters of the offering an option for a period of 30 days to purchase up to an additional $18,750,000 of shares of common stock at the public offering price, less the underwriting discount. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed.
RARE: 54.10 (+0.12)
Nasdaq stocks posting largest percentage increases
AP - Tue Jan 27, 5:09PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
LGCY: 13.35 (+0.51), HTBX: 5.83 (+0.22), ADXS: 7.18 (+0.06), LSCC: 6.10 (+0.02), ALDX: 11.01 (-0.25), RARE: 54.10 (+0.12), SIMG: 7.25 (-0.01), VTAE: 14.40 (+0.82), VBLT: 14.11 (+0.24), CRRC: 22.96 (+0.22), PLNR: 6.63 (-0.07), VNR: 18.09 (+0.38)
Ultragenyx (RARE) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jan 14, 8:03AM CST
Ultragenyx (RARE) Shares March Higher, Can It Continue?
RARE: 54.10 (+0.12)
Ultragenyx Announces Intent to File for Conditional Approval in Europe for Sialic Acid Extended-Release Tablets in Hereditary Inclusion Body Myopathy
GlobeNewswire - Mon Jan 12, 8:16AM CST
Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced its intent to file a Marketing Authorization Application (MAA) seeking conditional approval from the European Medicines Agency (EMA) for the use of six grams per day of sialic acid extended-release (SA-ER; UX001) tablets in the treatment of hereditary inclusion body myopathy (HIBM; also known as GNE myopathy). SA-ER is designed to replace the deficient sialic acid substrate in patients with HIBM, a rare, progressive muscle-wasting disease. Based on Scientific Advice recently received from the EMA's Committee for Medicinal Products for Human Use (CHMP), the company intends to file an MAA in the second half of 2015 for stabilization of upper extremity muscle strength.
RARE: 54.10 (+0.12)
After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Jan 07, 4:35PM CST
MPW: 14.64 (+0.14), WDFC: 82.95 (+0.21), SU: 31.62 (+0.30), PODD: 32.00 (-0.07), RECN: 17.46 (-0.15), RARE: 54.10 (+0.12), AFSI: 55.60 (-0.89), AGU: 108.58 (+1.60), ALXN: 182.29 (+6.02), BIND: 6.06 (+0.21)
Ultragenyx Announces License of Intellectual Property Related to the Treatment of Huntington's Disease With Triheptanoin
GlobeNewswire - Wed Jan 07, 3:42PM CST
Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced a license agreement with Inserm Transfert SA and Institut du Cerveau et de la Moelle Epiniere (ICM) for intellectual property related to the treatment of Huntington's disease with triheptanoin (UX007).
RARE: 54.10 (+0.12)
Ultragenyx to Present at the J.P. Morgan Healthcare Conference
GlobeNewswire - Mon Jan 05, 8:00AM CST
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company's Chief Executive Officer, will be presenting at the J.P. Morgan 2015 Healthcare Conference on January 13, 2015 at 10:00am PT in San Francisco.
JPM: 59.67 (+0.10), RARE: 54.10 (+0.12)
Nasdaq makes annual changes to Biotechnology Index
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 11:36AM CST
TTPH: 35.18 (-0.73), ZSPH: 46.77 (+3.42), AMRN: 1.18 (unch), OPHT: 51.11 (+0.12), AERI: 27.91 (+0.14), ASPX: 65.76 (+2.76), CNCE: 12.76 (-0.46), ICEL: 5.27 (+0.02), GWPH: 78.09 (+1.70), AUXL: 36.47 (-0.06), RTRX: 13.92 (+0.44), RCPT: 115.83 (-0.66), AAVL: 36.29 (+0.01), AKBA: 9.32 (+0.51), EXPR: 14.61 (+0.33), RARE: 54.10 (+0.12), RLYP: 33.98 (+0.60), PETX: 16.52 (-0.10), ENTA: 33.30 (-0.44), RDUS: 50.37 (+0.63), CARA: 10.96 (-0.03), FLML: 14.15 (+0.15), ALIM: 5.16 (unch), ANIP: 62.69 (-0.43), ICPT: 209.12 (+7.12), RVNC: 16.84 (+0.27), POZN: 6.95 (+0.15), FPRX: 24.63 (+0.63), ZFGN: 39.06 (+0.92), CRIS: 3.23 (+0.25), QLTI: 4.15 (unch), PCYC: 163.28 (+0.23), PTX: 8.63 (+0.01), CLDN: 16.45 (-0.05), RIGL: 2.47 (+0.05), HPTX: 26.83 (-0.05), AMPH: 12.76 (+0.02), INO: 6.80 (-0.15), VSAR: 18.04 (-0.55), FMI: 48.88 (+0.17), TBPH: 18.51 (+0.28), XLRN: 38.02 (+0.07), MGNX: 34.09 (+0.10), INSM: 17.40 (+0.69), ONTX: 2.27 (-0.02), ALDR: 26.06 (+0.18), SAGE: 41.03 (-0.07), KITE: 62.59 (+0.82), CGEN: 8.19 (+0.08), FOLD: 8.36 (-0.11), KPTI: 27.12 (-0.13)
Ultragenyx Phase 3 MPS 7 trial underway
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 10:34AM CST
RARE: 54.10 (+0.12)
Ultragenyx Announces Initiation of Phase 3 Study of Recombinant Human Beta-Glucuronidase in Mucopolysaccharidosis Type 7
GlobeNewswire - Mon Dec 15, 8:06AM CST
Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced the dosing of the first patient in the pivotal Phase 3 study of recombinant human beta-glucuronidase (rhGUS, UX003), an investigational therapy for the treatment of Mucopolysaccharidosis 7 (MPS 7, Sly syndrome).
RARE: 54.10 (+0.12)
Annual Changes to the NASDAQ Biotechnology Index
GlobeNewswire - Mon Dec 15, 6:10AM CST
The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) today announced the results of the annual re-ranking of the NASDAQ Biotechnology Index (Nasdaq:NBI), which will become effective prior to market open on Monday, December 22, 2014.
TTPH: 35.18 (-0.73), ZSPH: 46.77 (+3.42), AMRN: 1.18 (unch), OPHT: 51.11 (+0.12), AERI: 27.91 (+0.14), ASPX: 65.76 (+2.76), CNCE: 12.76 (-0.46), ICEL: 5.27 (+0.02), GWPH: 78.09 (+1.70), AUXL: 36.47 (-0.06), RTRX: 13.92 (+0.44), RCPT: 115.83 (-0.66), AAVL: 36.29 (+0.01), AKBA: 9.32 (+0.51), EXPR: 14.61 (+0.33), RARE: 54.10 (+0.12), ZGNX: 1.43 (+0.05), RLYP: 33.98 (+0.60), PETX: 16.52 (-0.10), ENTA: 33.30 (-0.44), RDUS: 50.37 (+0.63), CARA: 10.96 (-0.03), FLML: 14.15 (+0.15), ALIM: 5.16 (unch), ANIP: 62.69 (-0.43), ICPT: 209.12 (+7.12), RVNC: 16.84 (+0.27), POZN: 6.95 (+0.15), NDAQ: 49.48 (-0.27), FPRX: 24.63 (+0.63), CRIS: 3.23 (+0.25), ZFGN: 39.06 (+0.92), QLTI: 4.15 (unch), PCYC: 163.28 (+0.23), PTX: 8.63 (+0.01), CLDN: 16.45 (-0.05), RIGL: 2.47 (+0.05), HPTX: 26.83 (-0.05), AMPH: 12.76 (+0.02), INO: 6.80 (-0.15), VSAR: 18.04 (-0.55), FMI: 48.88 (+0.17), TBPH: 18.51 (+0.28), XLRN: 38.02 (+0.07), MGNX: 34.09 (+0.10), INSM: 17.40 (+0.69), ONTX: 2.27 (-0.02), ALDR: 26.06 (+0.18), SAGE: 41.03 (-0.07), KITE: 62.59 (+0.82), CGEN: 8.19 (+0.08), FOLD: 8.36 (-0.11), KPTI: 27.12 (-0.13)
Health Care IPO Market On Pace To Double Last Year
at Investor's Business Daily - Thu Dec 04, 3:09PM CST
The health care sector is looking very healthy in the department of initial public offerings. Histogenics (HSGX) on Wednesday was the 100th initial public offering in the health care sector this year, almost double the 53 in 2013. The sector accounts...
HSGX: 8.61 (-0.07), IMS: 25.68 (+0.22), RARE: 54.10 (+0.12), CTLT: 27.52 (-1.06), RWLK: 17.40 (-0.77)
Ultragenyx to Present at the Oppenheimer Healthcare Conference
GlobeNewswire - Wed Dec 03, 8:24AM CST
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that Tom Kassberg, the company's Chief Business Officer, will be presenting at the Oppenheimer 25 Annual Healthcare Conference on December 10, 2014 at 9:10am ET in New York.
RARE: 54.10 (+0.12)
Ultragenyx Pharmaceutical misses by $0.04
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 8:12AM CST
RARE: 54.10 (+0.12)
Ultragenyx Reports Third Quarter 2014 Financial Results and Corporate Update
GlobeNewswire - Mon Nov 10, 8:00AM CST
Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today reported its financial results and corporate update for the third quarter ended September 30, 2014.
RARE: 54.10 (+0.12)
Ultragenyx Announces Positive 36-Week Data From Phase 1/2 Study of Recombinant Human Beta-Glucuronidase in Mucopolysaccharidosis 7
GlobeNewswire - Tue Feb 10, 3:30PM CST
Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced the presentation of positive 36-week data from the Phase 1/2 study of recombinant human beta-glucuronidase (rhGUS, UX003), an investigational therapy for the treatment of Mucopolysaccharidosis 7 (MPS 7, Sly syndrome). The data are being presented in poster and oral presentations by Dr. Emil Kakkis, Chief Executive Officer of Ultragenyx, at the 11Annual WORLD Symposium in Orlando, Florida.
RARE: 54.10 (+0.12)
Ultragenyx prices public offering at USD54.00 per share
M2 - Fri Feb 06, 4:21AM CST
Biopharmaceutical company Ultragenyx Pharmaceutical (NasdaqGS:RARE) said on Thursday that it has priced a public offering of 3,000,000 common stock shares.
RARE: 54.10 (+0.12)
Ultragenyx prices equity offering
Seeking Alpha - at Seeking Alpha - Thu Feb 05, 8:11AM CST
RARE: 54.10 (+0.12)
Ultragenyx Announces Pricing of Public Offering of Common Stock
GlobeNewswire - Wed Feb 04, 6:09PM CST
Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced the pricing of its underwritten public offering of 3,000,000 shares of its common stock at a price to the public of $54.00 per share, before underwriting discounts. In addition, the company has granted the underwriters of the offering an option for a period of 30 days to purchase up to an additional 450,000 shares of the company's common stock at the public offering price, less the underwriting discount.
RARE: 54.10 (+0.12)
Ultragenyx to issue up to USD125m of common stock in public offering
M2 - Wed Feb 04, 5:24AM CST
Biopharmaceutical company Ultragenyx Pharmaceutical (NasdaqGS:RARE) Tuesday reported the start of its planned public offering of up to USD125m of shares of its common stock.
RARE: 54.10 (+0.12)
Ultragenyx Announces Proposed Public Offering of Common Stock
GlobeNewswire - Tue Feb 03, 3:37PM CST
Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that it has commenced an underwritten public offering of up to $125,000,000 of shares of its common stock. In addition, the company is expected to grant the underwriters of the offering an option for a period of 30 days to purchase up to an additional $18,750,000 of shares of common stock at the public offering price, less the underwriting discount. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed.
RARE: 54.10 (+0.12)
Nasdaq stocks posting largest percentage increases
AP - Tue Jan 27, 5:09PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
LGCY: 13.35 (+0.51), HTBX: 5.83 (+0.22), ADXS: 7.18 (+0.06), LSCC: 6.10 (+0.02), ALDX: 11.01 (-0.25), RARE: 54.10 (+0.12), SIMG: 7.25 (-0.01), VTAE: 14.40 (+0.82), VBLT: 14.11 (+0.24), CRRC: 22.96 (+0.22), PLNR: 6.63 (-0.07), VNR: 18.09 (+0.38)
Ultragenyx (RARE) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jan 14, 8:03AM CST
Ultragenyx (RARE) Shares March Higher, Can It Continue?
RARE: 54.10 (+0.12)
Ultragenyx Announces Intent to File for Conditional Approval in Europe for Sialic Acid Extended-Release Tablets in Hereditary Inclusion Body Myopathy
GlobeNewswire - Mon Jan 12, 8:16AM CST
Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced its intent to file a Marketing Authorization Application (MAA) seeking conditional approval from the European Medicines Agency (EMA) for the use of six grams per day of sialic acid extended-release (SA-ER; UX001) tablets in the treatment of hereditary inclusion body myopathy (HIBM; also known as GNE myopathy). SA-ER is designed to replace the deficient sialic acid substrate in patients with HIBM, a rare, progressive muscle-wasting disease. Based on Scientific Advice recently received from the EMA's Committee for Medicinal Products for Human Use (CHMP), the company intends to file an MAA in the second half of 2015 for stabilization of upper extremity muscle strength.
RARE: 54.10 (+0.12)
After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Jan 07, 4:35PM CST
MPW: 14.64 (+0.14), WDFC: 82.95 (+0.21), SU: 31.62 (+0.30), PODD: 32.00 (-0.07), RECN: 17.46 (-0.15), RARE: 54.10 (+0.12), AFSI: 55.60 (-0.89), AGU: 108.58 (+1.60), ALXN: 182.29 (+6.02), BIND: 6.06 (+0.21)
Ultragenyx Announces License of Intellectual Property Related to the Treatment of Huntington's Disease With Triheptanoin
GlobeNewswire - Wed Jan 07, 3:42PM CST
Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced a license agreement with Inserm Transfert SA and Institut du Cerveau et de la Moelle Epiniere (ICM) for intellectual property related to the treatment of Huntington's disease with triheptanoin (UX007).
RARE: 54.10 (+0.12)
Ultragenyx to Present at the J.P. Morgan Healthcare Conference
GlobeNewswire - Mon Jan 05, 8:00AM CST
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company's Chief Executive Officer, will be presenting at the J.P. Morgan 2015 Healthcare Conference on January 13, 2015 at 10:00am PT in San Francisco.
JPM: 59.67 (+0.10), RARE: 54.10 (+0.12)
Nasdaq makes annual changes to Biotechnology Index
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 11:36AM CST
TTPH: 35.18 (-0.73), ZSPH: 46.77 (+3.42), AMRN: 1.18 (unch), OPHT: 51.11 (+0.12), AERI: 27.91 (+0.14), ASPX: 65.76 (+2.76), CNCE: 12.76 (-0.46), ICEL: 5.27 (+0.02), GWPH: 78.09 (+1.70), AUXL: 36.47 (-0.06), RTRX: 13.92 (+0.44), RCPT: 115.83 (-0.66), AAVL: 36.29 (+0.01), AKBA: 9.32 (+0.51), EXPR: 14.61 (+0.33), RARE: 54.10 (+0.12), RLYP: 33.98 (+0.60), PETX: 16.52 (-0.10), ENTA: 33.30 (-0.44), RDUS: 50.37 (+0.63), CARA: 10.96 (-0.03), FLML: 14.15 (+0.15), ALIM: 5.16 (unch), ANIP: 62.69 (-0.43), ICPT: 209.12 (+7.12), RVNC: 16.84 (+0.27), POZN: 6.95 (+0.15), FPRX: 24.63 (+0.63), ZFGN: 39.06 (+0.92), CRIS: 3.23 (+0.25), QLTI: 4.15 (unch), PCYC: 163.28 (+0.23), PTX: 8.63 (+0.01), CLDN: 16.45 (-0.05), RIGL: 2.47 (+0.05), HPTX: 26.83 (-0.05), AMPH: 12.76 (+0.02), INO: 6.80 (-0.15), VSAR: 18.04 (-0.55), FMI: 48.88 (+0.17), TBPH: 18.51 (+0.28), XLRN: 38.02 (+0.07), MGNX: 34.09 (+0.10), INSM: 17.40 (+0.69), ONTX: 2.27 (-0.02), ALDR: 26.06 (+0.18), SAGE: 41.03 (-0.07), KITE: 62.59 (+0.82), CGEN: 8.19 (+0.08), FOLD: 8.36 (-0.11), KPTI: 27.12 (-0.13)
Ultragenyx Phase 3 MPS 7 trial underway
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 10:34AM CST
RARE: 54.10 (+0.12)
Ultragenyx Announces Initiation of Phase 3 Study of Recombinant Human Beta-Glucuronidase in Mucopolysaccharidosis Type 7
GlobeNewswire - Mon Dec 15, 8:06AM CST
Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced the dosing of the first patient in the pivotal Phase 3 study of recombinant human beta-glucuronidase (rhGUS, UX003), an investigational therapy for the treatment of Mucopolysaccharidosis 7 (MPS 7, Sly syndrome).
RARE: 54.10 (+0.12)
Annual Changes to the NASDAQ Biotechnology Index
GlobeNewswire - Mon Dec 15, 6:10AM CST
The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) today announced the results of the annual re-ranking of the NASDAQ Biotechnology Index (Nasdaq:NBI), which will become effective prior to market open on Monday, December 22, 2014.
TTPH: 35.18 (-0.73), ZSPH: 46.77 (+3.42), AMRN: 1.18 (unch), OPHT: 51.11 (+0.12), AERI: 27.91 (+0.14), ASPX: 65.76 (+2.76), CNCE: 12.76 (-0.46), ICEL: 5.27 (+0.02), GWPH: 78.09 (+1.70), AUXL: 36.47 (-0.06), RTRX: 13.92 (+0.44), RCPT: 115.83 (-0.66), AAVL: 36.29 (+0.01), AKBA: 9.32 (+0.51), EXPR: 14.61 (+0.33), RARE: 54.10 (+0.12), ZGNX: 1.43 (+0.05), RLYP: 33.98 (+0.60), PETX: 16.52 (-0.10), ENTA: 33.30 (-0.44), RDUS: 50.37 (+0.63), CARA: 10.96 (-0.03), FLML: 14.15 (+0.15), ALIM: 5.16 (unch), ANIP: 62.69 (-0.43), ICPT: 209.12 (+7.12), RVNC: 16.84 (+0.27), POZN: 6.95 (+0.15), NDAQ: 49.48 (-0.27), FPRX: 24.63 (+0.63), CRIS: 3.23 (+0.25), ZFGN: 39.06 (+0.92), QLTI: 4.15 (unch), PCYC: 163.28 (+0.23), PTX: 8.63 (+0.01), CLDN: 16.45 (-0.05), RIGL: 2.47 (+0.05), HPTX: 26.83 (-0.05), AMPH: 12.76 (+0.02), INO: 6.80 (-0.15), VSAR: 18.04 (-0.55), FMI: 48.88 (+0.17), TBPH: 18.51 (+0.28), XLRN: 38.02 (+0.07), MGNX: 34.09 (+0.10), INSM: 17.40 (+0.69), ONTX: 2.27 (-0.02), ALDR: 26.06 (+0.18), SAGE: 41.03 (-0.07), KITE: 62.59 (+0.82), CGEN: 8.19 (+0.08), FOLD: 8.36 (-0.11), KPTI: 27.12 (-0.13)
Health Care IPO Market On Pace To Double Last Year
at Investor's Business Daily - Thu Dec 04, 3:09PM CST
The health care sector is looking very healthy in the department of initial public offerings. Histogenics (HSGX) on Wednesday was the 100th initial public offering in the health care sector this year, almost double the 53 in 2013. The sector accounts...
HSGX: 8.61 (-0.07), IMS: 25.68 (+0.22), RARE: 54.10 (+0.12), CTLT: 27.52 (-1.06), RWLK: 17.40 (-0.77)
Ultragenyx to Present at the Oppenheimer Healthcare Conference
GlobeNewswire - Wed Dec 03, 8:24AM CST
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that Tom Kassberg, the company's Chief Business Officer, will be presenting at the Oppenheimer 25 Annual Healthcare Conference on December 10, 2014 at 9:10am ET in New York.
RARE: 54.10 (+0.12)
Ultragenyx Pharmaceutical misses by $0.04
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 8:12AM CST
RARE: 54.10 (+0.12)
Ultragenyx Reports Third Quarter 2014 Financial Results and Corporate Update
GlobeNewswire - Mon Nov 10, 8:00AM CST
Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today reported its financial results and corporate update for the third quarter ended September 30, 2014.
RARE: 54.10 (+0.12)
